Controlling the mitochondrial gatekeeper for effective chemotherapy.
Fennell
D A
DA
Department of Experimental Haematology, St Bartholomew's and The Royal London School of Medicine, UK.
Cotter
F E
FE
D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D058787:GABA-A Receptor Antagonists; D005786:Gene Expression Regulation; D019254:Genes, bcl-2; D006801:Humans; D007425:Intracellular Membranes / Q000187:drug effects; D007546:Isoquinolines / Q000627:therapeutic use; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D010087:Oxides / Q000627:therapeutic use; D011524:Protoporphyrins / Q000627:therapeutic use
D001152:Arsenicals; D058787:GABA-A Receptor Antagonists; D007546:Isoquinolines; D016376:Oligonucleotides, Antisense; D010087:Oxides; D011524:Protoporphyrins; C028025:protoporphyrin IX; D000077237:Arsenic Trioxide; C037850:PK 11195